Compare Hinge Health Inc. Class A Common Stock (HNGE) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs MobilEye Global Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B), while MobilEye Global Inc trades at $7.1 (market cap $5.97B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and MobilEye Global Inc for 15 Days on average.
| HNGE | MBLY | |
|---|---|---|
Market Cap | $8.48B | $5.97B |
Volume | 879,799 | 6,124,531 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.14 | $15.33 |
52-Week Low | $31.17 | $6.56 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $8.10B | $4.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Mobileye Global (MBLY) trades at $7.02, up 2.63% with recent earnings beats but faces bearish technical signals and significant net losses. The stock shows strong institutional support with 57.7% analyst buy ratings and a $10.77 consensus target, yet profitability remains challenged with a -201.5% net margin. Recent news highlights ADAS business momentum and autonomous vehicle expansion opportunities.
The outlook presents a high-risk opportunity with potential upside from autonomous driving adoption, but investors face substantial execution risks and ongoing losses. Key catalysts include Porsche launch progress and robotaxi developments, while competitive pressures and cash flow volatility remain significant concerns for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
